MEDNAX (MD) Tops Q4 EPS by 8c; Issues 2022 EBITDA Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts MD Hot Sheet
Join SI Premium – FREE
MEDNAX (NYSE: MD) reported Q4 EPS of $0.52, $0.08 better than the analyst estimate of $0.44. Revenue for the quarter came in at $499 million versus the consensus estimate of $483.83 million.
On a preliminary basis, Mednax anticipates that its 2022 Adjusted EBITDA, as defined above, will be at least $270 million.
For earnings history and earnings-related data on MEDNAX (MD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Oppenheimer Holdings (OPY) Reports Q3 EPS of $1.81
- Pediatrix Medical Group Reports Third Quarter Results
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
